Press Releases

Press Releases

April 28, 2020
CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors
SOUTH SAN FRANCISCO, Calif. , April 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® therapeutic technology platform, today
Additional Formats
April 27, 2020
CytomX Therapeutics to Announce First Quarter 2020 Financial Results
-Teleconference Scheduled for May 7, 2020, at 5:00 p.m. ET- SOUTH SAN FRANCISCO, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based
Additional Formats
March 25, 2020
CytomX Therapeutics Announces New Employment Inducement Grant
SOUTH SAN FRANCISCO, Calif. , March 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® therapeutic technology platform, today
Additional Formats
March 16, 2020
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , March 16, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today
Additional Formats
Displaying 11 - 20 of 27